Related Experiment Video
Updated: May 6, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Advanced kidney cancer: treating the elderly
Fable Zustovich1, Giacomo Novara
1IRCCS Istituto Oncologico Veneto, Medical Oncology, Via Gattamelata, 64-35128 Padua, Italy.
Abstract:
Advancing age represents the primary risk factor for renal tumors. Despite findings on the inhibition of angiogenesis that have led to six new drugs to treat metastatic renal cell carcinoma, elderly patients have not been fully represented in clinical trials. In addition, current opinions regarding nephrectomy in elderly patients are conflicting. Available data refer to the efficacy and safety of sorafenib, sunitinib, everolimus, bevacizumab and temsirolimus in patients aged 65 years and older; safety and efficacy data are available only for sunitinib, sorafenib,and everolimus in patients aged 70 years and older and only sorafenib has safety data for patients aged 75 years and older. A different approach based on evaluating comorbidities at baseline, risk of drug interactions and the impact of antitumor treatment in patients with polytherapy regimen is discussed. A decision-making algorithm is proposed to facilitate the selection of the best therapy for kidney tumors for a specific elderly patient profile.
Insights
Elderly patients with kidney tumors are underrepresented in clinical trials. This study proposes a new approach to select optimal cancer treatments for older adults, considering their unique health factors.
Area of Science:
- Oncology
- Geriatrics
- Nephrology
Background:
- Advancing age is the primary risk factor for renal tumors.
- Elderly patients are underrepresented in clinical trials for renal cell carcinoma treatments.
- Current opinions on nephrectomy for elderly patients are conflicting.
Purpose of the Study:
- To address the lack of representation of elderly patients in clinical trials for renal tumors.
- To evaluate the efficacy and safety of existing treatments in older populations.
- To propose a novel decision-making algorithm for selecting kidney tumor therapies in elderly patients.
Main Methods:
- Reviewing available efficacy and safety data for angiogenesis inhibitors in patients aged 65 and older.
- Analyzing data for specific drugs (sunitinib, sorafenib, everolimus) in patients aged 70 and older.
- Considering comorbidities, drug interactions, and polytherapy regimens in elderly patients.
Main Results:
- Limited safety and efficacy data exist for elderly patients, especially those over 70 and 75.
- Sorafenib has the most available safety data for patients aged 75 and older.
- A comprehensive approach evaluating patient-specific factors is needed.
Conclusions:
- Existing clinical trial data inadequately represents elderly patients with renal tumors.
- A tailored approach considering comorbidities and polytherapy is crucial for treatment selection.
- The proposed decision-making algorithm aims to optimize kidney tumor therapy for individual elderly patients.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
Drug Dosing: Geriatric Patients
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Kidney Transplant I: Introduction
Chronic Kidney Disease I: Introduction
